Kornimate/medical-research-clean huggingface dataset:
feasibility of virtual reality games using head-mounted display on patients with brain disorders

Conditions: Upper Extremity Dysfunction; Brain Diseases

Summary: because virtual reality can provide more enriched environment, repetitive goal-oriented tasks, and increased patients' interest and motivation, it is expected to stimulate neuroplasticity of injured brain and promote recovery in patients with brain disorders. on the other hand, immersive virtual reality using a head-mounted display has not yet been attempted in the rehabilitation of patients with brain disorders. in addition to the benefits of existing virtual reality or game rehabilitation, immersive virtual reality can further enhance brain plasticity, such as the effect of mirror therapy or action observation, through self-awareness of the body in the virtual space. the purpose of this study is to investigate the feasibility of applying the immersive virtual reality using a head-mounted display in patients with upper extremity dysfunction due to brain disorders.


Eligibility criteria:
inclusion criteria: * patients with upper extremity dysfunction due to brain disorders (eg, stroke, traumatic brain injury, brain tumor, etc.) * patient who can move the upper limb against the gravity (mrc grade 3 or above in both shoulder and elbow flexion) * patient who can maintain stable sitting position * adults over 18 years old * patients who voluntarily agreed to participate in the study exclusion criteria: * a moderate-to-severe cognitive impairment score of 18 or less in mini-mental status examination (mmse) * peripheral nerve injury, joint disease, other diseases of the upper extremity dysfunctions other than brain disorders * patients with a history of severe dizziness or epilepsy * patients with other medical illness that are difficult to participate in the study
pharmacokinetics and safety/tolerability of yy-201 in comparison to dutasteride and tadalafil

Conditions: Benign Prostatic Hyperplasia

Summary: a randomized, open label, single dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety/tolerability of yy-201 in comparison to dutasteride and tadalafil administered in healthy male volunteers


Eligibility criteria:
inclusion criteria: * age 19 to 45 years * bmi score 19 kg/m2 to 28 kg/m2 * sbp \< 140 mmhg and ≤ 90 mmhg or dbp \< 90 mmhg and ≥ 50 mmhg * eligible according to the laboratory results of hematology, blood chemistry and urinalysis * voluntarily signed the informed consent form exclusion criteria: * gastrointestinal diseases or surgery which may affect absorption of the investigational products within 6 months * history of hypersensitivity * history of cardiovascular disease * history of degenerative retina disease * lactose intolerance * medical history of vision loss * clinically significant disorders of allergy, drug hypersensitivity reaction, hepatobiliary system, kidney, neurology, respiratory, hemato-oncology, endocrine, dermatology, urology, ophthalmology, psychiatry, musculo-skeletal system, immunology, otorhinolaryngology, and cardiovascular system * donated whole blood (transfusion, apheresis etc..) within 60 days * participated and administered the investigational products in other clinical trial within 90 days * taking drugs which may affect clinical trial within 30 days * smoked more than 10 cigarettes a day for past 30 days * excessive alcohol consumption (\> 3 units/week, 1 unit) * taking food which may affect clinical trial within 7 days * positive result from urinary test * positive result from serum test * clinically significant disorders result from electrocardiography test * not eligible due to investigator's judgments

Keywords: dutasteride tadalafil
vaginal progesterone in twins with short cervix

Conditions: Premature Birth

Summary: a multicenter, double-blind, placebo-controlled randomized clinical trial of vaginal progesterone to prevent early preterm birth in twin pregnancy with short cervix.

this is a placebo-controlled, double-blind, randomized clinical trial of asymptomatic women with twin pregnancy and a cervix length 10 mm to 25 mm discovered on a routine screening transvaginal sonogram between 20w0d to 24w0d gestational age. women will be randomized in either the in-patient or out-patient setting (1:1) to a daily vaginal application of micronized progesterone cream(200 mg)vs. placebo to determine if daily vaginal progesterone administration reduces the risk of preterm birth prior to 34w0d of gestation.

Eligibility criteria:
inclusion criteria: * gestational age between 20w0d and 24w0d * twin pregnancy, diamniotic-dichorionic, both twins living * cervical length 10 mm to 25 mm discovered by a screening transvaginal ultrasound exam exclusion criteria: * mother less than 18 years of age * uterine contractions of 40 seconds duration or more, 10 or more per hour * rupture of fetal membranes (leakage of amniotic fluid one or both sacs) * ongoing vaginal bleeding * any condition likely to cause serious neonatal morbidity independent of gestational age, including: 1. fetal malformation likely to require surgery 2. fetal malformation involving vital organs 3. fetal viral infection 4. hydrops fetalis 5. discordance in estimated fetal weight more than 10% 6. velamentous insertion of umbilical cord of either twin 7. placenta previa of either placenta * any contraindication to continuing the pregnancy * cervical cerclage in place or planned * any contraindication to vaginal micronized progesterone, including: 1. known sensitivity to progesterone or any of the other ingredients 2. liver dysfunction or disease 3. known or suspected malignancy of breast or genital organs 4. active thromboembolic disorder, or history of hormone-associated thromboembolic disorder

Keywords: premature birth twins short cervix
a multimodal predictive recurrence score for patients with clear cell renal cell carcinoma

Conditions: Renal Cell Carcinoma, Clear Cell

Summary: the main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccrcc patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.


Eligibility criteria:
inclusion criteria: * patients with malignant renal tumours must have postoperative pathological confirmation of renal clear cell carcinoma with pathological tnm stage ⅰ-ⅲ; * have available preoperative imaging * have available post-operative pathological paraffin samples or he-stained tissue sections * must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone exclusion criteria: * the patient's tumour type cannot be determined on the basis of histopathological sections * simultaneous combination of primary tumours at other sites; * no regular follow-up imaging data * cases in which other factors led the investigator to believe that enrolment was inappropriate * cases that met all the inclusion criteria of the appeal and did not meet all the exclusion criteria were selected for this study

Keywords: renal cell carcinoma multimodal artificial intelligence prognosis deep learning multicentre study
home monitoring of patients with rheumatoid arthritis - an ehealth development study

Conditions: Rheumatoid Arthritis

Summary: a two-step multi-centre study with 240 rheumatoid arthritis patients.

a two-step multi-centre study containing: a test-retest study including 180 patients filling in questionnaires and performing joint assessments to assess reliability of patient generated data and an agreement study focusing on questionnaires and joint assessments performed by 60 patients, a medical student, a physician and by an ultrasound-examinator assessing agreement between the four assessors

Eligibility criteria:
inclusion criteria: * diagnosed with ra ≥ 12 months * das28-crp \< 5,1 exclusion criteria: * dementia or other linguistic/cognitive/physical deficiency that prevents participation * vision impairment that prevents the use of the devices and computer
antibiotic therapy with or without g-csf in treating children with neutropenia and fever caused by chemotherapy

Conditions: Fever, Sweats, and Hot Flashes; Neutropenia; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: antibiotics may decrease the side effects of neutropenia and fever caused by chemotherapy. colony-stimulating factors such as g-csf may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. it is not yet known whether antibiotic therapy plus g-csf is more effective than antibiotic therapy alone for treating side effects caused by chemotherapy. purpose: randomized phase iii trial to compare the effectiveness of antibiotic therapy with or without g-csf in treating children who have neutropenia and fever that are caused by chemotherapy.

objectives: * determine whether filgrastim (g-csf) used in addition to standard antibiotic therapy accelerates time to resolution of febrile neutropenia in children receiving chemotherapy. outline: this is a randomized study. patients are randomized to one of two treatment arms. * arm i: patients receive standard antibiotic therapy. * arm ii: patients receive treatment as in arm i. patients also receive filgrastim (g-csf) subcutaneously or iv once a day until at least 2 consecutive afebrile days have passed and absolute neutrophil count is at least 500/mm3. patients are followed for 3 days. projected accrual: a total of 200 patients (100 per treatment arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically diagnosed cancer with fever and chemotherapy-induced neutropenia (absolute neutrophil count no greater than 500/mm3) * acute onset of fever of at least 38.8 degrees celsius that is not related to the administration of blood products or pyrogenic substances * no acute myelogenous leukemia * no myelodysplastic syndrome * no solid tumor with bone marrow involvement patient characteristics: age: * 21 and under performance status: * not specified life expectancy: * not specified hematopoietic: * see disease characteristics hepatic: * creatinine less than 1.5 times upper limit of normal renal: * not specified other: * no patients in septic shock * no prolonged fever of unknown origin prior concurrent therapy: biologic therapy: * no concurrent filgrastim (g-csf) or sargramostim (gm-csf) * see chemotherapy chemotherapy: * no prior or concurrent myeloablative chemoradiotherapy with bone marrow or peripheral stem cell rescue endocrine therapy: * not specified radiotherapy: * see chemotherapy * no prior radiotherapy to marrow reserves (i.e., craniospinal and/or pelvic irradiation) surgery: * not specified other: * at least 7 days since prior iv antibiotics

Keywords: unspecified childhood solid tumor, protocol specific fever, sweats, and hot flashes neutropenia
effect of usage time of helmet in babies with deformational plagiocephaly

Conditions: Non Synostotic Plagiocephaly

Summary: investigating the optimal usage time of helmet therapy is the aim of the study. participants will be babies with deformational plagiocephaly. plagiocephalometric assesments will be utilize to follow improvement of head symmetry. scales asking sensational integration and severity of plagiocephaly will also be used. time of daily usage will be follow with daily asking the caregivers how long the baby wear the helmet in a day. participants will follow for three months.

investigating the optimal usage time of helmet therapy is the aim of the study. participants will be babies with deformational plagiocephaly. plagiocephalometric assesments will be utilize to follow improvement of head symmetry. scales asking sensational integration and severity of plagiocephaly will also be used. time of daily usage will be follow with daily asking the caregivers how long the baby wear the helmet in a day. participants will follow for three months. after the follow period completed, participants will be allocated two groups; avarage using 15-18 hours a day and avarage using 19-23 hours a day. results will be compared for the two groups and correlation between the time of usage and cranial symmetry will be compare.

Eligibility criteria:
inclusion criteria: have deformational plagiocephaly consent from caregivers age between 1 day to 7 months exclusion criteria: have another systemic, neurologic or orthopedic problem

Keywords: deformational plagiocephaly, orthotics, helmet
near-infrared spectroscopy-based neurofeedback as adjunct to mindfulness-oriented recovery enhancement in persons with chronic pain

Conditions: Chronic Pain Syndrome; Opioid Use

Summary: the primary aim of this pilot trial is to enhance the efficacy of the mindfulness-oriented recovery enhancement (more) intervention by adding neurofeedback (nf) of the orbitofrontal cortex (ofc) as an adjunct to the savoring component of more. we hypothesize that the use of nf to train ofc responses during savoring will amplify patients' ability to savor and thereby increase brain responsivity to natural rewards; such enhanced reward responding will in turn be associated with improvements in clinical outcomes (e.g., pain, analgesic use).


Eligibility criteria:
inclusion criteria: 1. ≥18 years of age, 2. ability to understand and speak the english language 3. current chronic pain-related diagnosis exclusion criteria: 1. mindfulness training experience (e.g., participation in mbsr/mbrp) 2. neurofeedback experience 3. current cancer diagnosis 4. having a psychiatric or medical condition that precludes the ability to provide informed consent or participation in outpatient treatment (e.g., psychosis, mania, acute intoxication) 5. suicidal ideation with a plan in the past week, or a suicide attempt in the past 3 months 6. unwilling, unable, or unlikely to complete study procedures (e.g., planned major surgery, anticipated move, travel barrier) 7. communication or cognitive impairment that limits participation in group treatment or study procedures
heart rate variability at the emergency department

Conditions: Heart Rate Variability; Emergency Department

Summary: in this study investigators want to examine if heart rate variability at hospital entry predicts prognosis in participants with severe disease.

predictive parameters that can predict the outcome are very scarce. vital parameters such as heart rate, blood pressure, saturation, etc. can be normal for a long time or only slightly changed, even in seriously ill patients. heart rate variability is a parameter that can be used as a measure of autonomic dysfunction. lower heart rate variability is associated with increased mortality and morbidity according to recent studies. heart rate variability could thus be used to identify the need for intervention and treatment more quickly. in this study, we want to investigate whether there is indeed a relationship between heart rate variability at admission to the emergency department and eventual mortality and morbidity in critically ill patients. therefore, heart rate variability will be determined in patients admitted to the emergency department who were triaged in red or orange according to the manchester triage system (internationally validated triage system that is also used in the emergency department at uz gent). subanalyses will be made for patients with trauma, sepsis, pneumonia, cva and acute myocardial infarction. determination of heart rate variability will be done by ekg monitoring during the first 5 minutes and after 3 hours. there are several parameters that can reflect heart rate variability. both frequency domain measurements and non-linair measurements will be determined. use will be made of the kubios programme, a free programme that can determine these different parameters on the basis of ekg monitoring. patients who are resuscitated on arrival will be excluded, as well as patients in vkf, as the heart rate variability on arrival cannot be determined for these two groups. demographic data (age, sex,...), history and home medication, vital parameters (heart rate, blood pressure, saturation, temperature, respiratory rate) and some lab data (lactate, crp) will also be collected. the primary outcome will be mortality after 30 days. secondary outcomes that will be studied are the total duration of hospital stay and the duration of stay in the intensive care unit, as well as the need for life-saving interventions (need for surgery, ventilation, inotropics, pci or thrombolysis). by collecting these data, we want to find out whether heart rate variability is a good predictor of outcome, and thus the need for icu admission, faster invasive interventions,... during this study, the patient's management will remain unchanged.

Eligibility criteria:
inclusion criteria: patients with (possible) sepsis, myocardial infarction, cerebrovascular accident, polytrauma or covid 19 pneumonia who were triaged red or orange following the manchester triage system exclusion criteria: patients with cardiac arrest or arrhythmia at arrival
prevalence of hemorrhagic myocardial infarction in the united states

Conditions: Acute Myocardial Infarction

Summary: registry analysis for prevalence of hemorrhagic myocardial infarction in the united states


Eligibility criteria:
inclusion criteria: * acute myocardial infarction - stemi primary pci availability of lab parameters and/or cmr
post-preeclampsia renal project: study of nephroprotection in women having suffered preeclampsia

Conditions: Renal Alteration

Summary: the purpose of the post-preeclampsia renal project is to investigate the renal function of preeclamptic women after delivery, and to determine whether the anti-hypertensive drug named benazepril efficiently improves the dysfunctions observed.

several epidemiological studies suggest that the risk of death from cardiovascular causes among women with preeclampsia may be increased, and that preeclampsia contrary to what has been long thought, is not cured with delivery. preeclampsia has long been considered a 2-stage disease, stage one corresponding to an impaired placental perfusion resulting from abnormal spiral artery remodeling, and stage two corresponding to the maternal manifestations of disease, characterized by hypertension and proteinuria. however, preeclampsia might include an additional, 3rd stage, that of the post-partum period (gammill \& roberts, 2007) this phase deserves to be investigated. in particular, it is crucial to determine whether the changes that occur in renal hemodynamics during preeclampsia are reversible after more than 6 weeks, and whether pec women are salt-sensitive after delivery. the link between chronic kidney disease and cardiovascular mortality is well established. an independent, graded association exists between a reduced gfr and the risk of death, cardiovascular events, and hospitalization (go et al, 2004). besides, salt-sensitivity is associated with an increased cardiovascular and renal risk (franco \& oparil, 2006). the renal post pec study aims at establishing if the renal dysfunctions that occur in pec women can be reversed by the administration of inhibitors of the renin-angiotensin system that are known to improve cardiovascular and renal risk profiles in hypertensive patients. by virtue of their potent renal vasodilatory properties and favourable remodelling of the gbm, ace inhibitors may improve salt-sensitivity, endothelial function, renal plasma flow and gfr, and general renal prognosis in women who experienced from preeclampsia.

Eligibility criteria:
pre-selection criteria: * normotensive women with no proteinuria before the 20th week of gestation and * women with hypertension (bp ≥140/90 mm hg) and proteinuria (≥ 0.3 g /24h or 2++ dipstick) after the 20th week of gestation inclusion criteria: * clearance of creatinine ≤ 80 ml/min (gault et cockcroft) * serum creatinine ≥ 80 µmol/l * microalbuminuria comprised between 30 and 300 mg/d and/or a urinary spot with microalbuminuria/creatinine ratio ≥ 3.5 and/or macroalbuminuria (24h urinary albumin excretion ≥ 0.500 mg) * bp ≥ 140/90 mm hg or ongoing antihypertensive treatment * crp ≥ 4 mg/dl exclusion criteria: * those unlikely to co-operate in the study * those who refuse to use appropriate contraceptive measures during the treatment period (intrauterine device, oral contraceptives, condom, diaphragm) * those with a history of pre-term delivery * those with known history of severe allergic reaction * those who consume drugs * aged \< 18 years old

Keywords: renal function consecutive to pre-eclampsia
intermittent treatment with sulfadoxine-pyrimethamine for malaria control in infants

Conditions: Malaria; Anemia

Summary: the purpose of this study is to assess the effectiveness of intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine to reduce the numbers of malaria attacks, episodes of anemia, and the overall morbidity and mortality

in order to define the effectiveness of intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine, a novel principle of malaria intervention, the following parameters are evaluated: i) the level of protection from malaria attacks and episodes of anemia during the treatment period, ii) the level of protection from severe malaria during the treatment period, iii) the effect on malaria morbidity after sustaining treatment, iv) the decrease of overall morbidity and mortality, including the number of hospital admissions and visits of hospital outpatient departments v) the influence of the intervention on the development of drug resistances, vi) the impact of the intervention on the development of immunity, vii) the possible influence of the intervention on sub-clinical organ dysfunction due to chronic plasmodium falciparum infection. parts of the study are performed in collaboration with the laboratory of research, hospital albert schweitzer, lambaréné, gabon and the school of medicine and health sciences, university of development studies, tamale, ghana

Eligibility criteria:
inclusion criteria: * informed consent by parent/guardian (written or oral) * permanent residentship in the study area * age of 3 months +/-4 weeks exclusion criteria: * hypersensitivity to sulfonamides or pyrimethamine (skin rashes, evidence of hemolysis including dark urine and/or purpura, presumptive signs of bone marrow depression such as sore throat and/or mouth ulcers) * other severe adverse events related to pyrimethamine-sulfadoxine application * signs of severe hepatic or renal dysfunction not due to malaria * other reasons after decision of the study physician

Keywords: malaria anemia ipti intermittent preventive treatment in infants sulfadoxine-pyrimethamine chemoprophylaxis ghana